Literature DB >> 3570038

Effects of olsalazine in the jejunum of the rat.

A Q Mohsen, D Mulvey, J D Priddle, D S Parsons, D P Jewell.   

Abstract

Olsalazine (ADS) is the azo-linked dimer of 5-aminosalicylic acid (5-ASA). It is of value for the management of patients with ulcerative colitis but may be associated with increasing diarrhoea in a few. This study examines the effect of 5-ASA and ADS on small intestinal transport systems of the rat. Krebs-Ringer-bicarbonate solution was circulated through the lumen of a jejunal segment and the appearance of fluid, glucose and lactate on the serosal surface was shown to be linear over a two hour period. Addition of 5-ASA (10 mmol/l) or ADS (5 mmol/l and 10 mmol/l) caused a significant inhibition both of fluid transport (p less than 0.001), and of the appearance of glucose (p less than 0.001) and lactate (p less than 0.001 for 5 mmol/l and 10 mmol/l ADS, p less than 0.01 for 10 mmol/l 5-ASA). The uptake of glucose by rings of rat jejunum was shown to be markedly reduced by ADS. Experiments substituting glucose with either sucrose of 2-aminoisobutyric acid showed that ADS (5 mmol/l, 10 mmol/l) also inhibited the serosal appearance of fructose and the amino acid. These results show that 5-ASA and ADS, at concentrations which could be expected in the jejunum of patients receiving therapeutic doses, are able to inhibit small intestinal transport systems. The resulting increase in load on the diseased colon could be important for the pathogenesis of diarrhoea.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570038      PMCID: PMC1432687          DOI: 10.1136/gut.28.3.346

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  Application of high performance liquid chromatography to study transport and metabolism of nucleic acid derivatives by rat jejunum in vitro: endogenous washout.

Authors:  D S Parsons; M I Shaw
Journal:  Q J Exp Physiol       Date:  1983-01

2.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

3.  Absorption and metabolism of fructose by rat jejunum.

Authors:  P A Holloway; D S Parsons
Journal:  Biochem J       Date:  1984-08-15       Impact factor: 3.857

4.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

5.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors:  A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

6.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

7.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

8.  Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.

Authors:  H Sandberg-Gertzén; G Järnerot; K Bukhave; K Lauritsen; J Rask-Madsen
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

  8 in total
  10 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.

Authors:  A Ireland; C H Mason; D P Jewell
Journal:  Gut       Date:  1988-06       Impact factor: 23.059

3.  Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

Authors:  S P Travis; C Tysk; H J de Silva; H Sandberg-Gertzén; D P Jewell; G Järnerot
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

Review 4.  Medical treatment of ulcerative colitis: scoring the advances.

Authors:  C J Hawkey; A B Hawthorne
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

Review 5.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

6.  Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects.

Authors:  A H Raimundo; D H Patil; P G Frost; D B Silk
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

7.  Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?

Authors:  C Scheurlen; H Allgayer; W Kruis; E Erdmann; T Sauerbruch
Journal:  Clin Investig       Date:  1993-04

8.  Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.

Authors:  S Kiilerich; K Ladefoged; T Rannem; P J Ranløv
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

9.  Effect of olsalazine on sodium-dependent bile acid transport in rat ileum.

Authors:  A Chawla; P I Karl; R N Reich; G Narasimhan; G A Michaud; S E Fisher; B L Schneider
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

Review 10.  Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.

Authors:  G Järnerot
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.